To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Higher cost & lack of analgesia benefit with liposomal bupivacaine vs bupivacaine/morphine

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
January 2017

Higher cost & lack of analgesia benefit with liposomal bupivacaine vs bupivacaine/morphine

Vol: 6| Issue: 1| Number:8| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

The AAHKS Clinical Research Award: Liposomal Bupivacaine and Periarticular Injection Are Not Superior to Single-Shot Intra-articular Injection for Pain Control in Total Knee Arthroplasty

J Arthroplasty. 2016 Sep;31(9 Suppl):22-5

Contributing Authors:
RK Jain MD Porat GG Klingenstein JJ Reid RE Post SD Schoifet

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

207 patients scheduled for total knee arthroplasty were randomized to postoperative analgesia with either periarticular liposomal bupivacaine, periarticular bupivacaine and morphine, or intraarticular bupivacaine and morphine. Patients were assessed postoperatively for mean pain during the hospital stay, maximum pain during the hospital stay, and mean morphine equivalents taken per 24 hours. The c...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue